News - Page 81 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article MINDCURE Announces Financial Results for the First Quarter of Fiscal 2023

USA – English

USA – English

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2023 USA – English USA – English

Post published:October 27, 2022
Post category:Press Release

Read more about the article Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference

Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference

Post published:October 26, 2022
Post category:Press Release

Read more about the article atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression

atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression

Post published:October 25, 2022
Post category:Press Release

Read more about the article Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs

Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs

Post published:October 24, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study

Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study

Post published:October 24, 2022
Post category:Press Release

Read more about the article Psychedelic Bulletin #120: Beckley Psytech Acquires Eleusis; A Look at COMPASS’ Phase 3 Design; New Psychedelic Drug Dev Scoops $22m Series A

Psychedelic Bulletin #120: Beckley Psytech Acquires Eleusis; A Look at COMPASS’ Phase 3 Design; New Psychedelic Drug Dev Scoops $22m Series A

Post published:October 24, 2022
Post category:Psychedelic Bulletin

Read more about the article Beckley Psytech Strengthens Pipeline and Development Team With Acquisition of Eleusis Therapeutics Limited

Beckley Psytech Strengthens Pipeline and Development Team With Acquisition of Eleusis Therapeutics Limited

Post published:October 24, 2022
Post category:Press Release

Read more about the article Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study

Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study

Post published:October 21, 2022
Post category:Press Release

Read more about the article atai Life Sciences Announces R&D Day Agenda

atai Life Sciences Announces R&D Day Agenda

Post published:October 21, 2022
Post category:Press Release

Read more about the article Psilera’s Award-Winning Co-Founders To Be Featured Speakers at Upcoming Industry Conferences Across the Country.

Psilera’s Award-Winning Co-Founders To Be Featured Speakers at Upcoming Industry Conferences Across the Country.

Post published:October 20, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.